Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02356965 · ClinicalTrials.gov registry record · Phase 2
Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction
A Phase 2 study, sponsored by iX Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02356965 is a Phase 2 study that has completed, run by iX Biopharma. The registered enrollment target is 80 participants.
The verdict
NCT02356965, a Phase 2 study, has completed, sponsored by iX Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of the study is to test two different doses of ketamine sub-lingual (under the tongue) wafer against placebo to see how effective the medication is to treat moderate to severe pain after wisdom tooth extraction.
Interventions
- DRUG Ketamine
- DRUG Placebo (for Ketamine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02356965
The ClinicalTrials.gov registry entry for NCT02356965 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is iX Biopharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT02356965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02356965 about?
NCT02356965 is a clinical study titled "Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction". The purpose of the study is to test two different doses of ketamine sub-lingual (under the tongue) wafer against placebo to see how effective the medication is to treat moderate to severe pain after wisdom tooth extraction.
What is the current status of trial NCT02356965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2014-12. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02356965?
The interventions under investigation include: Ketamine (DRUG), Placebo (for Ketamine) (DRUG).
Who is sponsoring clinical trial NCT02356965?
This trial is sponsored by iX Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.